文献速递心境障碍精神分裂症与精神病性障碍物质与行为成瘾

将神经丝轻链测量引入精神病学:当前证据、机遇与陷阱

Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls.
PubMed 文献 · Mol Psychiatry · 2024-03-19

本文介绍神经丝轻链(NfL)作为神经轴突损伤的血标志物,系统综述其在主要精神障碍中的脑脊液和血液水平研究,指出重性抑郁、双相障碍、精神病性障碍、神经性厌食和物质使用障碍患者血NfL较生理状态升高,但水平受诊断类别、临床阶段、患者亚组及人口学、临床和分析因素影响,需准确表征。

要点

  • 血NfL在重性抑郁、双相障碍、精神病性障碍、神经性厌食和物质使用障碍中较生理状态升高。
  • 血NfL水平在诊断实体、临床阶段和患者亚组间差异大,受多因素影响。
  • NfL可用于诊断预后算法、排除神经退行性疾病、评估脑毒性和纵向监测治疗反应。

核心结论

  • 当前证据提示重性抑郁、双相障碍、精神病性障碍、神经性厌食和物质使用障碍患者血NfL水平较生理状态升高。
  • 血NfL水平在诊断实体、临床阶段和患者亚组间差异大,并受人口学、临床和分析因素影响。

研究设计与样本

  • 本文为叙述性综述,简要介绍NfL作为神经轴突损伤标志物并系统综述近期关于主要精神障碍患者脑脊液和血NfL水平的研究。

主要发现

  • 重性抑郁、双相障碍、精神病性障碍、神经性厌食和物质使用障碍患者血NfL水平较生理状态升高。
  • 血NfL水平在诊断实体、临床阶段和患者亚组间差异大,受人口学、临床和分析因素影响。

临床怎么用

  • NfL测量可用于诊断和预后算法、排除神经退行性疾病、评估不同药物的脑毒性以及纵向监测治疗反应。

局限性

  • NfL水平个体间变异高且对其释放缺乏神经生物学理解是当前主要局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent introduction of new-generation immunoassay methods allows the reliable quantification of structural brain markers in peripheral matrices. Neurofilament light chain (NfL), a neuron-specific cytoskeletal component released in extracellular matrices after neuroaxonal impairment, is considered a promising blood marker of active brain pathology. Given its sensitivity to a wide range of neuropathological alterations, NfL has been suggested for the use in clinical practice as a highly sensitive, but unspecific tool to quantify active brain pathology. While large efforts have been put in characterizing its clinical profile in many neurological conditions, NfL has received far less attention as a potential biomarker in major psychiatric disorders. Therefore, we briefly introduce NfL as a marker of neuroaxonal injury, systematically review recent findings on cerebrospinal fluid and blood NfL levels in patients with primary psychiatric conditions and highlight the opportunities and pitfalls. Current evidence suggests an elevation of blood NfL levels in patients with major depression, bipolar disorder, psychotic disorders, anorexia nervosa, and substance use disorders compared to physiological states. However, blood NfL levels strongly vary across diagnostic entities, clinical stage, and patient subgroups, and are influenced by several demographic, clinical, and analytical factors, which require accurate characterization. Potential clinical applications of NfL measure in psychiatry are seen in diagnostic and prognostic algorithms, to exclude neurodegenerative disease, in the assessment of brain toxicity for different pharmacological compounds, and in the longitudinal monitoring of treatment response. The high inter-individual variability of NfL levels and the lack of neurobiological understanding of its release are some of the main current limitations. Overall, this primer aims to introduce researchers and clinicians to NfL measure in the psychiatric field and to provide a conceptual framework for future research directions.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bavato F, Barro C, Schnider LK, et al. Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls. Mol Psychiatry. 2024. PMID: 38503931. doi:10.1038/s41380-024-02524-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。